NCT05529901View on ClinicalTrials.gov

Japan Post Marketing Surveillance of the GORE® CARDIOFORM Septal Occluder

Active, not recruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions
StrokePFO - Patent Foramen OvaleCryptogenic StrokeTIA
Interventions
DEVICE

GORE® CARDIOFORM Septal Occluder

Patients for whom the device is used (implanted or used by not implanted) during the enrollment period of this post-marketing surveillance will be considered eligible for the study

Trial Locations (1)

700-8558

Okayama University Hospital, Okayama

All Listed Sponsors
lead

W.L.Gore & Associates

INDUSTRY